The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
File version
Author(s)
Butterworth, Alice S
Porter, Kimberly A
D'Amico, Ronald
Sawe, Fred
Shaffer, Doug
Siika, Abraham
Hosseinipour, Mina C
Stringer, Elizabeth
Currier, Judith S
Chipato, Tsungai
Salata, Robert
Lockman, Shahin
Eron, Joseph J
Meshnick, Steven R
McCarthy, James S
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
80728 bytes
File type(s)
application/pdf
Location
Abstract
HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for =48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.
Journal Title
PloS One
Conference Title
Book Title
Edition
Volume
7
Issue
4
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2012 Skinner-Adams et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License CCAL. (http://www.plos.org/journals/license.html)
Item Access Status
Note
Access the data
Related item(s)
Subject
Medical parasitology